Singapore, Feb. 11 -- Iambic, a US-based clinical-stage life science and technology company developing novel medicines using its artificial intelligence (AI)-driven discovery and development platform, has announced a multi-year technology and discovery collaboration agreement with Japan-based Takeda Pharma that will use Iambic's industry leading AI drug discovery models to advance a select set of high-priority small molecule programmes, initially in Takeda's Oncology and Gastrointestinal and Inflammation therapeutic areas.

Through the agreement, Takeda will also gain access to NeuralPLexer, Iambic's industry leading model for predicting protein-ligand complexes.

Under the terms of the agreement, Iambic will receive upfront, research cos...